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t is known that nuclear DNA helicase II (NDH II) links
CREB-binding protein directly to RNA polymerase II
holoenzyme,  and that this interaction is essential for
gene activation by CREB. Here, we report for the ﬁrst time
that some NDH II/RNA helicase A is a component of
promyelocytic leukemia nuclear bodies (PML NBs). An
autoimmune serum speciﬁc for PML NBs was identiﬁed
and used in immunoprecipitation experiments. NDH II
was present in the immunoprecipitates as shown by mass
spectrometry and by immunoblotting. Immunoﬂuorescence
and ultrastructural studies showed that NDH II colocalizes
with a small subset of PML NBs in control cells, however,
I
 
colocalizes with practically all bodies in interferon-
 
 
 
–
stimulated cells. After interferon stimulation, more PML NBs
were found to contain newly synthesized RNA, as indicated
by bromouridine incorporation. PML NBs also contain RNA
polymerase II. The association of NDH II with PML NBs was
transcriptionally dependent, and NDH II was present in all
bodies with nascent RNA. Blocking of mRNA synthesis
caused NDH II relocalization from nucleoplasm to nucleoli.
Based on the data, we suggest that NDH II recruitment to
PML NBs is connected with transcriptional regulation of
interferon-
 
 
 
–inducible genes attached to PML NBs.
 
Introduction
 
The nucleus of the eukaryotic cell is a complex organelle
compartmentalized into structural and functional domains.
The promyelocytic leukemia nuclear bodies (PML NBs)* are
nuclear multiprotein structures that are tightly bound to the
nuclear matrix (Chang et al., 1995). They are also referred to
as nuclear bodies, nuclear domain 10, Kr bodies, or promyelo-
cytic leukemia oncogenic domains (Ascoli and Maul, 1991;
Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994).
Cells typically contain 10–30 PML NBs per nucleus with
diameters between 0.2 and 1 
 
 
 
m, although their number
and size change during the cell cycle (Koken et al., 1995;
for review see Zhong et al., 2000a).
The promyelocytic leukemia gene product (PML) is
necessary for the proper formation of PML NBs (Ishov et
al., 1999). It is a ubiquitously expressed matrix-associated
nuclear phosphoprotein in which overexpression induces
growth suppression (Mu et al., 1994; Chang et al., 1995).
The PML gene was originally cloned as the t(15;17) chromo-
somal translocation partner of the retinoic acid receptor
(RAR
 
 
 
) in acute promyelocytic leukemia in which fusion
genes encoding PML-RAR
 
 
 
 and RAR
 
 
 
-PML fusion proteins
are generated (de The et al., 1991; Kakizuka et al., 1991;
Melnick and Licht, 1999). PML and PML-RAR
 
 
 
 proteins
have been shown to modulate the activity of a set of
downstream target genes, although it is not clear whether
this is a direct or indirect effect on transcription (Doucas
et al., 1993; Guiochon-Mantel et al., 1995; Wang et al.,
1998). As PML is invariably associated with the PML
NBs in all cell types studied so far, it has become a defining
marker for this structure.
The PML NBs contain several other proteins in addition
to PML. The first identified biochemical component of
PML NBs was the Sp100 nuclear matrix–associated protein,
an autoantigen in some patients with primary biliary cirrhosis
(Szostecki et al., 1990). This protein is an IFN-inducible
acidic protein that may transactivate a variety of promoters
(Guldner et al., 1992; Xie et al., 1993). Other components
of PML NBs identified so far include Sp140 (Bloch et al.,
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1996), ISG20 (Gongora et al., 1997), SUMO-1 (Boddy et
al., 1996; Sternsdorf et al., 1997), Int-6 (Desbois et al.,
1996), Bloom’s syndrome protein (BLM; Ishov et al.,
1999), Daxx (Ishov et al., 1999; Zhong et al., 2000b),
CREB-binding protein (CBP; LaMorte et al., 1998), pRB
(Alcalay et al., 1998), and p53 (Zhong et al., 2000a).
Type I and II IFNs dramatically increase the transcription
of the PML gene through an IFN-stimulated response ele-
ment present in the PML promoter (Lavau et al., 1995; Stad-
ler et al., 1995). IFNs also increase the expression of other
PML NB components, such as Sp100 and ISG20, as well as
the number of PML NBs (Guldner et al., 1992; Gongora et
al., 1997). This suggests a role for PML and PML NBs as a
part of the antiviral defense machinery activated by IFNs in
viral infections.
Although the biochemical function of PML and PML
NBs remains largely unknown, consistent evidence is ac-
cumulating for a role of PML in transcription regulation.
PML is a member of the RING finger family of proteins
that also includes other proteins involved in cellular
transformation and in the regulation of transcription,
such as transcriptional coactivator BRCA 1, the breast
cancer–specific tumor suppressor protein (Chapman and
Verma, 1996; Somasundaram et al., 1997). PML inter-
acts with CBP. It enhances transcriptional activation by
CBP (LaMorte et al., 1998; Doucas et al., 1999; von
Mikecz et al., 2000; Boisvert et al., 2001), and also by
certain nuclear receptors, including RAR
 
 
 
/RXR
 
 
 
, which
act as retinoic acid (RA)-dependent transcriptional acti-
vators (Liu et al., 1996b; Zhong et al., 1999). The analy-
sis of PML
 
 
 
/
 
 
 
 mice and cells has shown that the presence
of PML is crucial for the tumor growth–inhibitory activ-
ity of RA and for RA induction of myeloid differentia-
tion, as well as for the RA-dependent transcriptional acti-
vation of p21
 
WAF/CIP1
 
gene (Wang et al., 1998). It was
shown that p21
 
WAF/CIP1
 
gene regulates cell cycle progres-
sion and cellular differentiation, and can be activated by
nuclear receptors, including RAR
 
 
 
/RXR
 
 
 
 (Liu et al.,
1996a; Casini and Pelicci, 1999). PML is also involved in
the regulation of major histocompatibility complex ex-
pression (Zheng et al., 1998). The evidence for a role of
PML NBs in transcription comes from the demonstration
of nascent RNA polymerase (POL) II transcripts within
this nuclear body (LaMorte et al., 1998). However, more
recently, nascent RNA was detected in the periphery of
PML NBs, indicating that the surroundings of the PML
NBs are the sites of transcriptional activity (Boisvert et
al., 2000).
In this paper, we show that the nuclear DNA helicase II
(NDH II) is a member of the PML NBs proteins. Further-
more, evidence is presented that the association of NDH II
with PML NBs is transcriptionally dependent, and that the
nascent POL II transcripts are localized at the same PML
NBs where NDH II is recruited in INF-
 
 
 
–stimulated cells.
Our results also demonstrate functional differences between
individual PML NBs within one nucleus, as active transcrip-
tion takes place only at a subset of PML NBs. We propose
that NDH II recruitment to PML NBs is connected with
transcriptional regulation of INF-
 
 
 
–inducible genes at-
tached to PML NBs.
 
Results
 
Human autoimmune serum X103 immunoprecipitates 
protein complex of PML NBs
 
By screening a collection of human autoimmune sera using
indirect immunofluorescence on HeLa cells, a serum
(X103) showing a distinct nuclear pattern of brightly la-
beled spots was identified (Fig. 1 A). Double labeling of
HeLa cells with X103 serum and mAb 5E10 against PML
(Fig. 1 B) identified the spots as PML NBs showing com-
plete colocalization. IFN treatment (1,000 U/ml IFN-
 
 
 
for 24 h), which has been shown to increase the number of
PML NBs due to the IFN-induced up-regulation of PML
and Sp100 (Guldner et al., 1992; Lavau et al., 1995;
Grotzinger et al., 1996), resulted in an increase in the
number of X103-specific nuclear structures (Fig. 1, C and
D). An immunoprecipitation was performed using X103
serum coupled with protein G–Sepharose; the immuno-
precipitates were analyzed by SDS-PAGE followed by
Western blot or mass spectrometry. From two X103-posi-
tive bands in Western blots, IFN-
 
 
 
 treatment led to an in-
crease of a signal of one antigen (Fig. 1 E, lanes 1 and 2)
migrating at 
 
 
 
80 kD. The second antigen (signal of which
was not increased by IFN-
 
 
 
 treatment; data not shown)
was identified by mass spectrometry as the E2 component
of the pyruvate dehydrogenase multienzyme complex lo-
cated in mitochondria. It is known as M2 mitochondrial
autoantigen in patients with primary biliary cirrhosis
(Coppel et al., 1988). The IFN-
 
 
 
–stimulated antigen was
identified as Sp100 protein (Fig. 1 E, lane 3), a well-
known component of PML NBs in which expression is
highly up-regulated by IFNs (Guldner et al., 1992; Grotz-
inger et al., 1996). The electrophoretic mobility of Sp100
protein is highly aberrant, and it has been previously re-
ported to be faster than 100 kD (Szostecki et al., 1990;
Sternsdorf et al., 1997).
Because Sp100 protein is constitutively present in PML
NBs, we questioned whether the anti-Sp100 antibody
(X103) immunoprecipitates the protein complex of PML
NBs. The immunoprecipitates were screened for the pres-
ence of other PML NBs proteins by immunoblotting. The
blot shows (Fig. 1 F) that PML protein as well as BLM
(well-known components of PML NBs) coimmunoprecipi-
tate together with Sp100 from both control and IFN-
 
 
 
–
treated cells. Like Sp100, PML is highly stimulated by IFN-
 
 
 
but BLM protein is not, which corresponds with the litera-
ture data (Fig. 1 F, lanes 4 and 5). These results clearly show
that the protein complex of PML NBs is specifically immu-
noprecipitated by anti-Sp100 antibody (X103).
 
NDH II is a component of PML NBs
 
Apart from the proteins already characterized as PML NBs
associated, a new protein was identified in immunoprecipi-
tated protein complexes when cells were stimulated by IFN-
 
 
 
(Fig. 1 G). The protein migrating at 140 kD was identi-
fied by mass spectrometry as NDH II, alternatively named
RNA helicase A, a highly conserved member of the DEXH
superfamily of helicases (Lee and Hurwitz, 1993). This re-
sult was confirmed by Western blot of the same immuno-
precipitates using anti–NDH II antibody (Fig. 1 H). As 
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shown, NDH II is present in immunoprecipitates from
IFN-
 
 
 
–treated cells (Fig. 1, lane 3) but is not detectable in
immunoprecipitates from control cells (Fig. 1 H, lane 1).
On the other hand, BLM protein, used here as a control, is
present in both cases (Fig. 1, lanes 2 and 4). Moreover,
when immunoprecipitation using anti–NDH II antibody
coupled with protein G–Sepharose was performed and the
immunoprecipitates were analyzed by SDS-PAGE followed
by Western blot, Sp100 coimmunoprecipitated with NDH
II (data not shown). We conclude from these experiments
that NDH II is a component of the PML NBs complex after
IFN-
 
 
 
 stimulation.
 
IFN-
 
 
 
 treatment enhances colocalization of NDH II 
and PML NBs
 
To confirm the localization of NDH II in PML NBs in
situ, we used confocal laser scanning microscopy of control
and IFN-
 
 
 
–stimulated HeLa cells (1,000 U/ml IFN-
 
  
 
for
24 h) using the anti-Sp100 antibody (X103) and the anti–
NDH II antibody. Fig. 2 A shows that the nuclear distribu-
tion of NDH II in control cells can be observed as a fine
granular nucleoplasmic staining with a few larger foci.
Some (but not all) of the foci colocalize with PML NBs.
Similarly, some of the PML NBs do not colocalize with
NDH II at all. After IFN-
 
 
 
 stimulation (Fig. 2 B), NDH
II is detected in most PML NBs. Nevertheless, a consider-
able amount of NDH II remains distributed throughout
the nucleoplasm. Immunoelectron microscopy also clearly
demonstrated the presence of NDH II in PML NBs in
IFN-
 
 
 
–stimulated cells (Fig. 3 A). The ratio of colocaliza-
tion of PML NBs with NDH II foci in control and IFN-
 
 
 
–stimulated cells was quantified by measuring the fluores-
cence intensities overlap along profiles spanning the PML
NBs (Fig. 4). In control cells (Fig. 5), NDH II colocalizes
with only 19% of PML NBs, 28% of PML NBs colocalize
partially, and 
 
 
 
53% do not colocalize with NDH II foci.
In contrast, in IFN-
 
 
 
–treated cells NDH II colocalizes
with 79% of PML NBs, 
 
 
 
2% colocalize partially, and
19% of PML NBs do not colocalize with NDH II. Thus,
we conclude that NDH II is present in a subset of PML
NBs in control cells growing in standard conditions. How-
ever, IFN-
 
 
 
 stimulation causes recruitment of NDH II
into the majority of PML NBs.
 
NDH II association with PML NBs is interrupted by 
transcriptional inhibition
 
It has been shown previously that NDH II, functioning as a
bridging factor between the transcriptional coactivator CBP
and POL II, cooperates with CBP in mediating transcriptional
activation of target genes via CREB (Nakajima et al., 1997). In
addition, several studies suggest that PML and PML NBs may
play a role in transcription events (Vallian et al., 1997; La-
Morte et al., 1998), although no direct interaction between PML
and the transcription complex has been demonstrated. There-
fore, we tested whether the recruitment of NDH II into PML
 
immunoprecipitates from IFN-
 
 
 
–treated cells (lane 3) but not in 
control cells (lane 1). As a control, anti-BLM antibody was used 
to detect BLM protein (lanes 2 and 4) that is present in both cases.
Figure 1.  
 
NDH II is present in PML NBs upon IFN-
 
 
 
 induction.
 
 
(A and B) Double immunostaining of HeLa cells using autoimmune 
X103 serum (A) and mAb 5E10 (B) recognizing PML protein. PML 
and X103 antigen colocalize in PML NBs. (C and D) Effect of 
IFN-
 
 
 
 treatment on X103-specific antigen. Immunofluorescent 
localization of X103 antigen in HeLa cells: (A) control cells; 
(B) after treatment with IFN-
 
 
 
 (1,000 U/ml for 24 h). Bars, 2 
 
 
 
m. 
(E–H) Immunoprecipitation using X103 serum coupled with protein 
G–Sepharose followed by Western blot. The immunoprecipitates 
from control and IFN-
 
 
 
–treated cells (1,000 U/ml for 24 h) were 
analyzed using antibodies indicated above the blot. (E) IFN-
 
 
 
 
treatment led to an increase of a signal of X103-specific antigen 
migrating at 
 
 
 
80 kD (lanes 1 and 2) identified as Sp100 (lane 3). 
(F) PML protein (lanes 2 and 5), BLM (lanes 1 and 4), and POL II 
(lanes 3 and 6) are present in the immunoprecipitates from both 
control and IFN-
 
 
 
–treated cells. PML expression is highly enhanced 
by IFN-
 
 
 
 (lane 5) but BLM is not (lane 4). (G) 10% SDS-PAGE of 
immunoprecipitates from control and IFN-
 
 
 
–treated cells. NDH II 
(140 kD) coimmunoprecipitates with the PML NBs complex after 
IFN-
 
 
 
 stimulation. The gel was stained with Coomassie brilliant 
blue R-250 for total protein. (H) Western blot of the same immuno-
precipitates using anti–NDH II antibody confirmed its presence in  
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Figure 2.
 
Confocal micrographs of HeLa cells double labeled with the anti–NDH II antibody and anti-Sp100 antibody (X103).
 
 (A)
 
 
 
control 
cells; only some PML NBs colocalize with NDH II. (A1 and A2) Magnified views of indicated PML NBs show no colocalization (A1) or complete  
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NBs is related to transcriptional levels in a cell. The effect of
transcriptional inhibition on NDH II localization relative to
PML NBs was assessed by double labeling of control and IFN-
 
 
 
–treated cells (1,000 U/ml for 24 h) using the anti-Sp100 an-
tibody (X103) and the anti–NDH II antibody.
Treatment of cells with 
 
 
 
-amanitin (100 
 
 
 
g/ml for 3 h) at
doses that block mRNA synthesis (Nguyen et al., 1996) in-
duced rapid repositioning of NDH II, and the nuclear pattern
of NDH II localization was changed whether the cells were
(Fig. 2 D) or were not stimulated by IFN-
 
 
 
 (Fig. 2 C). In
both cases, the nucleoplasm is almost cleared of NDH II, and
NDH II completely disassociates from PML NBs. Instead, it
associates with nucleolar periphery. The results were identical
in cells treated with another transcriptional inhibitor actino-
mycin D (AMD) at doses that inhibit POL II transcription
(0.5 
 
 
 
g/ml for 3 h; Perry and Kelley, 1970; data not shown).
In contrast, when cells were treated with AMD at doses
that inhibit POL I but not POL II transcription (0.02 
 
 
 
g/
ml for 3 h), no changes in the nuclear pattern of NDH II
staining were observed in both nonstimulated (Fig. 2 E) and
IFN-
 
 
 
–stimulated cells (Fig. 2 F). Again, the effect of POL I
inhibition on NDH II nuclear distribution and its associa-
tion with PML NBs was quantified by measuring the fluo-
rescence intensities overlap along profiles spanning the PML
NBs. The frequency of the colocalization between PML
NBs and NDH II in cells treated with both IFN-
 
 
 
 and
AMD (0.02 
 
 
 
g/ml; 3 h) is similar to that of the cells treated
only with IFN-
 
 
 
 (Fig. 5). NDH II remains in the associa-
tion with PML NBs and colocalizes with 
 
 
 
75% of nuclear
bodies. Thus, the IFN-
 
 
 
–stimulated recruitment of NDH
II into the PML NBs is dependent on active transcription by
POL II, but not by POL I.
 
DNA transcription takes place at a subset of PML NBs
 
If transcription takes place at PML NBs, one would expect
the presence of POL II in these bodies. Indeed, POL II was
found to coimmunoprecipitate with the protein complex of
PML NBs from both control and IFN-
 
 
 
–treated cells (Fig.
1 F, lanes 3 and 6). Furthermore, POL II was present in
PML NBs in IFN-
 
 
 
–stimulated cells as shown by immuno-
electron microscopy (Fig. 3 B).
To demonstrate that the recruitment of NDH II into the
PML NBs is connected with transcription, the colocaliza-
tion of transcription foci with NDH II and PML NBs was
studied by confocal microscopy. Nascent transcripts were
labeled in vivo with bromouridine (BrU; 20 mM for 10
min) in control and in IFN-
 
 
 
–stimulated (1,000 U/ml
IFN-
 
  
 
for
 
 
 
24 h) HeLa cells. The sites containing nascent
BrRNA were then labeled with anti-BrdU antibody. For
triple immunofluorescence labeling, the cells were in addi-
tion stained with the anti-Sp100 antibody (X103) and
anti–NDH II antibody. In Fig. 6 (A and B), optical sec-
tions through the center of nuclei show distribution of
BrRNA in relationship to PML NBs and NDH II. In the
absence of IFN-
 
 
 
 stimulation in control cells, most PML
NBs do not overlap with transcription sites (Fig. 6, A and
C). After IFN-
 
 
 
 treatment (Fig. 6 B), some of the tran-
scription sites containing BrRNA enlarged, and they fre-
quently overlap with PML NBs as well as with NDH II
foci. PML NBs that are associated with discrete sites of
transcription containing BrRNA clearly colocalize with
NDH II (Fig. 6, B, E, and F). Identical results were ob-
tained when nascent transcripts were labeled using bro-
mouridine triphosphate (BrUTP) in gently permeabilized
cells. This method gives an advantage of known transcrip-
tion rate (Jackson et al., 1993), so we were sure that the lo-
calization of nascent transcripts was observed (Fig. 7). The
 
colocalization with NDH II (A2). The graph below shows the overlap of fluorescence intensity peaks along profiles spanning the PML NBs as 
indicated in the merged micrograph. (B) IFN-
 
 
 
–treated cells (1,000 U/ml for 24 h; 
 
 
 
IFN-
 
 
 
); NDH II is recruited to PML NBs. (B1) A magnified 
view of indicated PML NBs shows complete colocalization with NDH II foci. The graph below shows the overlap of fluorescence intensity peaks 
along profiles spanning the PML NBs as indicated in the merged micrograph. (C and D) After inhibition of POL II transcription with 
 
 
 
-amanitin 
(100 
 
 
 
g/ml for 3 h); (C) cells not stimulated with IFN-
 
 
 
 (
 
 
 
IFN-
 
 
 
/
 
  
 
-ama); (D) IFN-
 
 
 
–treated cells (1,000 U/ml for 24 h; 
 
 
 
IFN-
 
 
 
/
 
  
 
-ama). 
NDH II dissociates from PML NBs after inhibition of POL II transcription and is translocated to nucleolar periphery. (C1 and D1) Magnified 
views of indicated PML NBs show no colocalization with NDH II. (E and F) After treatment with AMD at concentration inhibiting only POL I 
transcription (0.02 
 
 
 
g/ml for 3 h); (E) cells not stimulated with IFN-
 
 
 
 (
 
 
 
IFN-
 
 
 
/
 
 
 
AMD 0.02 
 
 
 
g/ml); (F) IFN-
 
 
 
–treated cells (1,000 U/ml for 24 h; 
 
 
 
IFN-
 
 
 
/
 
 
 
AMD 0.02  g/ml). Inhibition of POL I transcription does not cause NDH II dissociation from PML NBs and its translocation to 
nucleolar periphery. (E1 and F1) Magnified views of indicated PML NBs show no colocalization with NDH II in IFN- –nonstimulated cells 
(E1), but complete colocalization in IFN- –stimulated cells (F1). The graph below shows the overlap of fluorescence intensity peaks along 
profiles spanning the PML NBs as indicated in the merged micrograph. Bar, 2  m.
Figure 3. Electron micrographs of IFN- –treated HeLa cells 
(1,000 U/ml for 24 h). (A) Double immunogold labeling using 
anti–NDH II (5-nm particles) and anti-Sp100 antibody (X103; 10-nm 
particles); NDH II localizes to PML NBs. (B) Double immunogold 
labeling using anti–POL II (5-nm particles) and anti-Sp100 antibody 
(X103; 10-nm particles). POL II localizes to PML NBs. Bars, 50 nm.468 The Journal of Cell Biology | Volume 158, Number 3, 2002
mutual relationship between PML NBs, NDH II, and the
sites containing nascent RNA was assessed by measuring
the three fluorescence intensities overlap along profiles
spanning PML NBs using the Leica confocal software (Fig.
8). In control cells,  9% of PML NBs contain both NDH
II and transcription sites, and 75% of bodies do not con-
tain either NDH II or nascent transcripts. About 16% of
bodies contain only NDH II but, most importantly, no
bodies contain only transcription sites. After IFN-  stimu-
lation, the number of PML NBs that colocalize with tran-
scription sites and NDH II increased up to 51% and the
number of PML NBs not containing either NDH II or na-
scent transcripts decreased. These data show that in addi-
tion to recruitment of NDH II into the PML NBs, some
prominent transcription foci are found associated with
PML NBs in IFN- –treated cells, particularly with those
containing NDH II. These results strongly imply the in-
volvement of the PML NBs in transcription processes trig-
gered by IFN stimulation.
Discussion
There has been considerable effort in recent years to define a
function for PML NBs, and more specifically, their involve-
ment in transcription. In this paper, we provided several
lines of evidence that NDH II is a component of PML NBs,
and that its association with PML NBs is interrupted by in-
hibition of POL II transcription. Furthermore, we have lo-
calized nascent RNA to the PML NBs in IFN- –treated
cells, and these transcripts were found to be associated with
the subset of PML NBs recruiting NDH II. These data
show that a fraction of NDH II is compartmentalized to the
PML NBs and strongly support an idea that the nuclear
bodies contribute to transcriptional regulation.
We have shown that the human serum X103 recognizes
Sp100 protein, and that it can be used to immunoprecipitate
the protein complex of PML NBs as confirmed by presence
of typical PML NBs proteins Sp100, PML, and BLM in the
immunoprecipitates. Immunofluorescence analysis revealed
differential distribution of NDH II in the nucleus. It is ho-
mogeneously distributed through the nucleus, which corre-
sponds to the published data (Zhang et al., 1999), or com-
partmentalized into foci that colocalize with a subset of PML
NBs. This colocalization is dramatically increased upon the
IFN-  treatment. Thus, we show here that a portion of
NDH II is present in PML NBs under certain conditions.
Another component of PML NBs, CBP, also was shown to
be a dynamic component of the bodies (Boisvert et al.,
2001). Hence, some components that are transient occu-
Figure 4. Complete and partial 
colocalization of PML NBs with NDH 
II. (A) The ratio of colocalization was 
quantified by measuring the fluorescence 
intensities overlap along profiles spanning 
the PML NBs using confocal software. 
(B and C) Magnified views of indicated 
PML NBs show complete colocalization 
(B) and partial colocalization (C) with 
NDH II foci. The colocalization was 
considered as complete when two 
peaks were overlapping and the maxima 
were shifted  20 nm (B; see graph). A 
side overlap of two peaks (maxima shifted 
 20 nm) was taken as a partial 
colocalization (C; see graph). Bar, 2  m.
Figure 5. Quantification of the colocalization of PML NBs and 
NDH II in control cells, in IFN- –stimulated cells, and after 
inhibition of POL I transcription (0.02  g/ml AMD; 3 h) performed 
in confocal images described in Fig. 2 (n   20). Because there is 
no colocalization after inhibition of POL II transcription (100  g/ml 
 -amanitin for 3 h; Fig. 2, C and D) the quantification was not 
performed in this case. In control cells, NDH II colocalizes 
completely with 19% of PML NBs, 28% of PML NBs colocalize 
partially, and  53% do not colocalize with NDH II foci. In 
IFN- –treated cells, NDH II colocalizes with 79% of PML NBs, 
 2% colocalize partially, and 19% of PML NBs do not colocalize 
with NDH II. After inhibition of POL I transcription, NDH II 
remains in the association with PML NBs and colocalizes with 
 75% of nuclear dots. Less than 5% of PML NBs colocalize 
partially, and 20% do not colocalize with NDH II. NDH II and PML nuclear bodies | Fuchsová et al. 469
pants of PML NBs may additionally function at multiple
sites throughout the nucleoplasm, and they can be recruited
to PML NBs under certain conditions, for instance, when
the transcriptional level of target genes is stimulated by IFN.
We showed that after transcriptional inhibition of POL II,
NDH II completely dissociates from PML NBs and associates
with the nucleolar periphery. However, inhibition of POL I
does not cause spatial repositioning of NDH II and its dissoci-
ation from PML NBs. Therefore, we conclude that IFN- –
stimulated recruitment of NDH II into the PML NBs is de-
pendent on an active POL II transcription. Moreover, we have
observed that after IFN-  treatment, transcription foci are also
found in association with PML NBs containing NDH II.
Thus, not only is the association of NDH II with PML NBs
transcriptionally dependent, but PML NBs associated with
NDH II also colocalize with discrete sites of transcription.
Similar observation has been made by LaMorte et al.
(1998). These authors localized nascent RNA to PML NBs.
In agreement with our results, not all of the PML NBs
within a cell accumulated nascent RNA, suggesting more
than one functional state of PML NBs. In their approach,
nascent RNA was labeled by incorporation of a fluorescein-
labeled nucleotide (FITC-UTP) microinjected into living
Hep-2 cells as well as at the ultrastructural level by EDTA-
Figure 6. Transcription sites imaged by 
confocal microscopy of HeLa cells. 
Nascent transcripts were labeled using 
BrU; triple immunostaining was 
performed using the anti-BrdU antibody, 
anti-Sp100 antibody (X103), and 
anti–NDH II antibody. (A) Cells not 
stimulated with IFN-  (control). BrRNA 
foci do not overlap with PML NBs. 
(C and D) Magnified views of indicated 
PML NBs. (B) IFN- –treated cells; BrRNA 
foci are found in association with a subset 
of PML NBs and NDH II foci. (E and F) 
Magnified views of indicated PML NBs 
show complete colocalization with 
BrRNA (E) and also with NDH II (F). The 
graphs below show the overlap of 
fluorescence intensity peaks along profiles 
spanning the PML NBs as indicated in 
the micrographs. For quantification of 
the results, see Fig. 8. Bar, 2  m.470 The Journal of Cell Biology | Volume 158, Number 3, 2002
regressive staining. In contrast, Boisvert et al. (2000) used
phosphorus mapping by electron spectroscopic imaging and
fluorine-substituted uridine incorporation detected by fluo-
rescence microscopy to show the presence of nascent RNA
at the periphery of this structure, but not in the protein
core of the PML NBs. In both cases, the observations were
made on cells not stimulated by IFN- . Here, we show us-
ing two labeling approaches (BrU and BrUTP incorpora-
tion) that after IFN-  treatment the association of tran-
scription foci with PML NBs increases from 9% of PML
NBs in control cells up to 51%. Thus, our work is able to
accommodate both sites of results and imply the involve-
ment of the PML NBs in transcription processes triggered
by IFN stimulation. Furthermore, we found POL II to lo-
cate in PML NBs and coimmunoprecipitate with PML
NBs proteins from both control and IFN- –treated cells.
This is consistent with the results by von Mikecz et al.
(2000) showing the presence of POL II and CBP in a sub-
set of PML NBs. Therefore, we suggest that NDH II re-
cruitment to PML NBs is connected with transcriptional
regulation of genes attached to PML NBs.
When considered in the light of recent studies on the func-
tion of NDH II, our results suggest that NDH II may repre-
sent a link between PML NBs and the transcription processes.
It has been shown that NDH II is a component of the POL II
holoenzyme that binds directly to CBP (Nakajima et al.,
Figure 7. Transcription sites imaged by 
confocal microscopy of HeLa cells. 
Nascent transcripts were labeled using 
BrUTP in gently permeabilized cells. 
Triple immunostaining was performed 
using the anti-BrdU antibody, anti-Sp100 
antibody (X103), and anti–NDH II 
antibody. (A) Cells not stimulated with 
IFN-  (control). BrRNA foci do not overlap 
with PML NBs. (C and D) Magnified 
views of indicated PML NBs. (B) IFN- –
treated cells; BrRNA foci are found in 
association with a subset of PML NBs 
and NDH II foci. (E and F) Magnified 
views of indicated PML NBs show 
complete colocalization with BrRNA (E) 
and also with NDH II (F). The graphs 
below show the overlap of fluorescence 
intensity peaks along profiles spanning 
the PML NBs as indicated in the merged 
micrographs. Bars, 2  m. NDH II and PML nuclear bodies | Fuchsová et al. 471
1997). It functions as a bridging element for the attraction of
the transcriptional coactivator CBP to POL II complex. This
CBP–NDH II interaction is essential for CREB-dependent
transcriptional activation of target genes. Our data are also in
agreement with the fact that a fraction of CBP was shown to
be compartmentalized to PML NBs through its direct associa-
tion with PML, although the precise mechanism whereby
PML modulates CBP function is yet unknown (Doucas et al.,
1999). These results raise the intriguing possibility that upon
transcriptional activation, for instance by IFN- , components
of the transcriptional regulatory complexes are transiently re-
cruited to the nuclear bodies, to take part in transcription of
genes associated with PML NBs. Because the complex forma-
tion between CBP and POL II requires NDH II, we can spec-
ulate that NDH II recruited into PML NBs links the tran-
scriptional coactivator CBP modulated by PML to POL II.
Interferon-stimulated gene factor-3 (ISGF-3), a multipro-
tein, IFN- –activated transcription factor consisting of a 48-
kD DNA binding protein and two proteins termed Stat1 and
Stat2 (for signal transducers and activators of transcription),
binds to IFN-  signal response elements and activates the
transcription of cellular antiviral defense genes. Stat2 was
shown to interact specifically with CBP, indicating that Stat2-
containing ISGF-3 complex may function in transcription ac-
tivation partly through the action of CBP (Bhattacharya et al.,
1996). The fact that NDH II binds CBP to POL II complex
and our observation that NDH II recruitment by PML NBs
is sensitive to the IFN-  stimulation speaks in favor of in-
volvement of PML NBs in transcription of the IFN- –stimu-
lated genes. This is consistent with the data showing a cooper-
ation of CBP and Stat2 in signaling induced by IFN- .
Nonuniform appearance of PML NBs may lead to a new
consideration as to the subclasses of PML NBs that differ in
their composition and function. Presented data showed that
not all of PML NBs are equivalent, and that they may have
more than one functional state. This is consistent with the
earlier observation that not all of PML NBs within a cell ac-
cumulate nascent RNA (LaMorte et al., 1998). Speculation
could be made that the recruitment of the respective PML
NBs–associated protein into the nuclear bodies under certain
conditions may modulate their cellular function. Indeed, a
dynamic mechanism for protein recruitment to these nuclear
domains controlled by the SUMO-1 modification state of
PML has already been suggested, although in this case a role
of PML NBs as nuclear depots for a number of proteins was
postulated (Ishov et al., 1999). However, the differential re-
cruitment of CBP to PML NBs through its direct association
with PML was also demonstrated, showing that PML can
function as a CBP cofactor in CBP-mediated activation of
transcription (Doucas et al., 1999). We can speculate that
PML NBs may represent storage sites of NDH II and other
components of transcriptional complexes used for associated
genes transcribed at PML NBs, similarly to nuclear speckles
containing a reservoir of splicing factors. On the other hand,
rather than storage sites they can actively participate in tran-
scriptional regulation. Our data speak in favor of the latter.
Even though further analysis will be necessary to elucidate
the role of PML NBs, we suggest that the recruitment of
NDH II into PML NBs is functionally linked with the con-
tribution of these structures to the transcription of specific
genes, possibly such as antiviral defense genes.
To understand the role of PML NBs in the control of
transcription, it is critical to clarify how individual PML NBs
components participate in these processes. Identification of
NDH II in PML NBs, which is a component of POL II ho-
loenzyme, bridging POL II and CBP, reveals an exciting di-
rect link between transcriptional machinery and PML NBs.
It will be critical to determine whether the association of
NDH II with PML NBs can serve as the regulatory element.
The identification of the genes expressed at/in PML NBs and
the use of PML
 /  cells to test whether there is an accumula-
tion of NDH II and POL II with Sp100 at IFN up-regulated
gene clusters could further shed a light on the mechanisms
by which PML NBs could regulate transcription.
Materials and methods
Cells, growth conditions, and transcription inhibitors
HeLa cells in monolayer cultures were grown in DME (Sevapharma) con-
taining 5% (vol/vol) FBS and antibiotics at 37 C in a humidified 5% CO2
atmosphere. Suspension cultures of HeLa cells were grown in S-MEM
(Sigma-Aldrich) supplemented with 5% FBS (vol/vol), 1 mM sodium pyru-
vate, nonessential amino acids, and antibiotics. For IFN-  induction, expo-
nentially growing cells were exposed for 24 h to 1,000 U/ml IFN-  (inter-
feronum   -2b; Schering-Plough Corporation). For inhibition of POL II
transcription,  -amanitin (Sigma-Aldrich) was added to the culture me-
dium at a final concentration of 100  g/ml for 3 h (Nguyen et al., 1996).
AMD (Sigma-Aldrich) was added for 3 h at final concentrations of either
0.02  g/ml for inhibition of POL I transcription or 0.5  g/ml for inhibition
of POL II transcription (Perry and Kelley, 1970).
Antibodies
Human autoimmune serum X103, positive for PML NBs, was obtained from
the Institute of Rheumatology with the patient’s consent and according to
the ethical guidelines of the state. The following antibodies were used:
mouse mAb 5E10 against PML protein (a gift from Dr. R. van Driel, E.C.
Slater Institute for Biochemical Research, University of Amsterdam, Nether-
lands; Stuurman et al., 1992), the rabbit anti-Sp100 (Sp-26) antiserum (ob-
tained from Dr. T. Sternsdorf, Max Planck Institute for Biochemistry, Martins-
ried, Germany; Szostecki et al., 1990), the rabbit polyclonal anti–NDH II
antibody (Zhang et al., 1995) donated by Dr. S. Zhang (Institute of Molecu-
lar Biotechnology, Jena, Germany), the rabbit polyclonal anti-BLM anti-
body (Neff et al., 1999), and the mouse mAb against POL II (a gift from Dr.
M. Vigneron, Institute of Genetics and Molecular and Cell Biology, Illkirch,
France). BrRNA was immunolabeled with anti-BrdU mAb (6  g/ml; clone
Figure 8. Significant number of PML NBs associate with 
transcription sites after IFN-  induction. Quantification of the 
colocalization of PML NBs with NDH II and transcription sites in 
control and IFN- –stimulated cells performed in confocal images 
described in Fig. 6 (n   20). In control cells, 75% of PML NBs do not 
contain either NDH II or nascent transcripts,  9% of bodies contain 
both NDH II and transcription sites, and 16% of bodies contain only 
NDH II; no bodies contain only transcription sites. After IFN-  
treatment, the number of PML NBs colocalizing with transcription 
sites and NDH II increases up to 51%, whereas the number of 
PML NBs not containing either NDH II or nascent transcripts 
decreases to 30%.472 The Journal of Cell Biology | Volume 158, Number 3, 2002
BMC9318; Boehringer). The secondary antibodies were donkey anti–
mouse, anti–rabbit, or anti–human IgG conjugated with FITC, Cy3, LRSC,
or Cy5 (1:100 dilution; Jackson ImmunoResearch Laboratories).
Immunofluorescent microscopy
Cells grown as a monolayer were fixed in acetone at  20 C (3 min) fol-
lowed by 20 min in 4% PFA in PBS. After washing with PBS, cells were in-
cubated with primary antibody (1 h), washed with PBS, and incubated
with secondary antibody (45 min) at RT. DNA was stained with DAPI (0.2
 g/ml in PBS for 10 min; Boehringer). Immunofluorescence was visualized
using either a conventional fluorescence microscope (Vanox-S; Olympus)
or a confocal laser scanning microscope (TCS SP; Leica). In the first case,
pictures were captured by a chilled CCD camera (model C5985;
Hamamatsu Corporation). The systems were carefully tested for the over-
lap of the three optical channels. This is documented also in Fig. 6 (C–F),
where no leakage between optical channels is present. Image files were
processed with Adobe Photoshop
®. The ratio of colocalization was quanti-
fied by measuring the fluorescence intensities overlap along profiles span-
ning the PML NBs using Leica confocal software (Fig. 4). The colocaliza-
tion was considered complete (Fig. 4 B) when two peaks were overlapping
and the maxima were shifted  20 nm. A side overlap of two peaks (max-
ima shifted  20 nm) was taken as a partial colocalization (Fig. 4 C).
Electron microscopy
HeLa cells grown in suspension were treated with IFN-  as described in
the first paragraph of Materials and methods. Cells were pelleted, fixed,
and embedded in LR White
TM resin (Polysciences, Inc; Hozak et al., 1994).
The ultrathin sections were double immunolabeled with the anti-Sp100
antibody (X103) and the rabbit anti–NDH II antibody or the mouse anti–
POL II mAb. The primary antibodies were visualized using 5-nm gold-
conjugated antibodies to rabbit or mouse IgG and 10-nm gold-conjugated
antibodies to human IgG (dilution 1:30; Jackson ImmunoResearch Laborato-
ries). Sections were contrasted with a saturated solution of uranyl acetate
and examined using an electron microscope (Philips Morgagni, FEI)
equipped with a CCD MegaView II camera (Soft Imaging System).
Western blot analysis
Protein samples were separated on 10% SDS-PAGE gels according to
Laemmli (1970). Proteins were transferred to nitrocellulose membranes
as described by Towbin et al. (1979). The blots were blocked with 5%
nonfat dried milk and 0.5% BSA in TBS (0.02 M Tris-HCl and 0.5 M
NaCl, pH 7.5) for 2 h at RT. After an overnight incubation with primary
antibodies, nitrocellulose membranes were treated with alkaline phos-
phatase–conjugated secondary antibodies recognizing mouse, human, or
rabbit IgG (Sigma-Aldrich) diluted 1:3,000 in TBS supplemented with
2.5% nonfat dried milk and 0.25% BSA for 1 h at RT. After extensive
washes with TBS containing 0.05% Tween 20, proteins were visualized
by color development with 5-bromo-4-chloro-3-indolyl phosphate/
nitrobluetetrazolium (Sigma-Aldrich).
Immunoprecipitation of proteins under nondenaturing conditions
Immunoprecipitation was performed as described previously (Lukas and
Bartek, 1998), except that after binding the antibodies to the protein G–Seph-
arose beads, they were cross-linked with the protein G via a bifunctional
coupling reagent dimethylpimelimidate (Sigma-Aldrich) as described by
Harlow and Lane (1988). All steps were performed on ice or at 4 C with
antiproteases (1 mM PMSF, 1  g/ml leupeptin, and 0.5  g/ml pepstatin).
The immunoprecipitates were analyzed either by Western blotting or by
SDS-PAGE followed by mass spectrometry.
Mass spectrometry
Coomassie brilliant blue R-250–stained protein bands were digested by se-
quencing grade trypsin (50 ng/ l; Promega) in a cleavage buffer containing
0.01% 2-mercaptoethanol, 0.1 M 4-ethylmorpholine acetate, pH 8.1, 10%
ACN, and 1 mM CaCl2. Digestion was performed overnight at 37 C, and
the resulting peptides were extracted with 30% ACN/1% TFA and sub-
jected to mass spectrometric analysis.
Mass spectra were measured on a mass spectrometer (BIFLEX MALDI-
TOF; Bruker Daltonics) equipped with a nitrogen laser (337 nm) and grid-
less delayed extraction ion source. Ion acceleration voltage was 19 kV,
and the reflectron voltage was set to 20 kV. Spectra were calibrated exter-
nally using the monoisotopic [M   H]
  ion of peptide standard somatosta-
tin (Sigma-Aldrich). A saturated solution of  -cyano-4-hydroxy-cinnamic
acid in 50% ACN/0.2% TFA was used as a MALDI matrix. 1  l of matrix
solution was mixed with 1  l of the sample on the target, and the droplet
was allowed to dry at ambient temperature.
Detection of transcription sites
For labeling of nascent transcripts with BrU, HeLa cells were grown as mono-
layers in DME containing 5% (vol/vol) FBS and BrU (20 mM; Sigma-Aldrich)
for 10 min to allow incorporation, rinsed in ice-cold medium and PBS, and
immediately fixed. The labeling of nascent transcripts with BrUTP was per-
formed as described previously (Pombo et al., 1999). In brief, cells were lysed
by addition of saponin (final concentration, 1 mg/ml; S-7900; Sigma-Aldrich)
in PB-BSA (physiological buffer [mM]: 100 potassium acetate, 30 KCl, 10
Na2HPO4, 1 MgCl2, 1 Na2ATP, 1 DTT, and 0.2 PMSF, pH 7.4 [Jackson et al.,
1993] supplemented with 100 mg/ml BSA and 10 U/ml human placental
RNase inhibitor) for 5 min, preincubated in PB-BSA (5 min, 35 C), and tran-
scription was initiated by adding a transcription mixture to give final concen-
trations of 100  M of CTP, GTP, BrUTP, and 0.3 mM MgCl2 (10 min, 35 C).
Cells were fixed (20 min, 4 C) in 4% PFA in Sörensen buffer (0.1 M sodium/
potassium phosphate buffer, pH 7.3) supplemented with 0.5% Triton X-100.
BrRNA was immunolabeled as described above. Images were collected using
a confocal laser scanning microscope (TCS SP; Leica) and processed as de-
scribed in the first paragraph of Materials and methods.
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